References
- Runyon BA. Care of Patients with Ascites. N Engl J Med. 1994;330(5):337–342.
- Garrison RN, Kaelin LD, Galloway RH, et al. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986;203(6):644–651.
- Parsons SL, Lang MW, Steele RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol. 1996;22(3):237–239.
- Runyon BA. Malignancy-related ascites and ascitic fluid ‘humoral tests of malignancy.’ J Clin Gastroenterol. 1994;18(2):94–98.
- Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945–949.
- Ramamoorthy V, Rubens M, Saxena A, et al. Prevalence and inpatient hospital outcomes of malignancy-related ascites in the United States. Am J Hosp Palliat Med. 2021;38(1):47–53.
- Gerbes AL, Jüngst D, Xie YN, et al. Ascitic fluid analysis for the differentiation of malignancy-related and nonmalignant ascites. Proposal of a diagnostic sequence. Cancer. 1991;68(8):1808–1814.
- Moore GE, Sandberg AA, Watne AL. The comparative size and structure of tumor cells and clumps in the blood, bone marrow, and tumor imprints. Cancer. 1960;13:111–117.
- Kusamura S, Baratti D, Zaffaroni N, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12–18.
- Levy AD, Shaw JC, Sobin LH. Secondary tumors and tumorlike lesions of the peritoneal cavity: imaging features with pathologic correlation. Radiographics. 2009;29(2):347–373.
- Sharma V, Jha DK, Rohilla M, et al. ‘Rollover’ abdominal paracentesis versus standard technique: protocol of a crossover randomized comparative trial. Future Oncol. 2021;17(26):3425–3431.
- Sun J, Chang Y-X, Niu C-Y. Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites. Tumor Biol. 2017;39(11):101042831772684.
- Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg. 2005;83(1):6–14.
- Chu DZJ, Lang NP, Thompson C, et al. Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–367.
- Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104–1109.
- Gupta S, Sodhani P, Jain S. Cytomorphological profile of neoplastic effusions: an audit of 10 years with emphasis on uncommonly encountered malignancies. J Cancer Res Ther. 2012;8(4):602–609.
- Choudry HA, Pai RK, Shuai Y, et al. Impact of cellularity on oncologic outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for pseudomyxoma peritonei. Ann Surg Oncol. 2018;25(1):76–82.
- Yamada S, Takeda T, Matsumoto K. Prognostic analysis of malignant pleural and peritoneal effusions. Cancer. 1983;51(1):136–140.
- Zhang F, Feng Z, Zhang Y, et al. Determination of the optimal volume of ascitic fluid for the precise diagnosis of malignant ascites. Saudi J Gastroenterol. 2019;25(5):327–332.
- Bhanvadia VM, Santwani PM, Vachhani JH. Analysis of diagnostic value of cytological smear method versus cell block method in body fluid cytology: study of 150 cases. Ethiop J Health Sci. 2014;24(2):125–131.
- Tyagi R, Gupta N, Bhagat P, et al. Impact of SurePath® liquid-based preparation in cytological analysis of peritoneal washing in practice of gynecologic oncology. J Cytol. 2017;34(2):95–100.